Resiquimod Gel

Resiquimod Topical Gel

When applied topically to the antigen injection site, Resiquimod acts as a TLR 7/8 agonist to stimulate immune activation as evidenced by Th1 cytokine production, enhanced antibody responses and CTL activation.

• Demonstrated adjuvant activity
• Toxicology and clinical data packages to support development available
• Ability to enter Phase 1 studies quickly
• Enhanced therapeutic window due to topical delivery
• Stable and cost-effective to manufacture